Patient characteristics
| Study | n | Design | Age (years) | Female (%) | Population | F/U(m) | Mortality | Composite | MI (%) | HTN (%) | HF (%) | DM (%) | Killip >1 | Smoking | β-block | ACEi | H chol | IHD | Statin | Antiplatelets |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ersbøll et al14 | 849 | Prosp | 62±12 | 229 (27) | Post-AMI, | 30 (24–32) | All-cause mortality | CV death and HF hosp | 849 (100) | 373 (84) | 28 (3.2) | 100 (11.7) | 86 (10) | 588 (70) | NA | NA | NA | NA | 213 (35) | 558 (92.5) |
| Munk et al10 | 576 | Prosp | 63±12 | 130 (22.5) | STEMI | 24 (13–61) | All-cause mortality | Death, HF hosp, CVA, AMI | 576 (100) | 195 (33.8) | NA | 59 (23) | 38 (16) | 323 (56) | NA | NA | NA | NA | NA | NA |
| Bertini et al11 | 1060 | Prosp | 67 (58–74) | 321 (30) | Ischaemic CM | 31 | Death, HF hosp | 1060 (100) | 459 (43) | 420 (40) | 298 (20) | NA | 253 (24) | 740 (69) | 896 (84) | 440 (41) | 71 (12.3) | NA | NA | |
| Antoni et al15 | 659 | Prosp | 60±12 | 142 (21) | AMI | 21±13 | All-cause mortality | Reinfarction, HF hosp, RVS | 659 (100) | 203 (31) | NA | 64 (10) | NA | 331 (50) | 575 (92) | 612 (98) | 131 (20) | NA | NA | NA |
| Woo et al17 | 98 | Prosp | 63±11 | 33 (33.6) | STEMI | 13±3.8 | Death, HF hosp | 98 (100) | 58 (59) | NA | 26 (26.5) | 24 (24.4) | 50 (51) | 62 (63.2) | 77 (78.5) | 19 (19.3) | NA | 774 (73) | 627 (59) | |
| Stanton et al6 | 546 | Prosp | 60.9±11 | 196 (35) | Unselected | 62.±18 | All-cause mortality | NA | NA | 282 (51.6) | 24 (4.4) | 107 (19.6) | NA | 122 (22.3) | 217 (39.7) | NA | 279 (51) | 49 (7.4) | 657 (98) | 627 (100) |
| Iacoviello et al5 | 308 | Prosp | 64±13 | 70 (23) | HF | 26±13 | All-cause mortality | HF hosp, CV death, malignant arrhythmia, heart Tx | NA | 60 (19.4) | 308 (100) | 23 (7.4) | NA | NA | 94 (30.5) | 91 (29.5) | NA | 5 (5.1) | 80 (81.6) | 98 (100) |
| Nahum et al18 | 125 | Prosp | 63±16 | 28 (23) | HF | 8.8±6 | Mortality, HF hosp, cardiac Tx, mechanical ventilation | NA | NA | 125 (100) | NA | NA | NA | NA | NA | NA | 248 (45.4) | NA | NA | |
| Cho et al21 | 201 | Prosp | 63±11 | 72 (35) | HF | 39±17 | Cardiac death, HF hosp | NA | 115 (57.5) | 201 (100) | NA | NA | NA | 142 (70.6) | 177 (88) | NA | 42 (13.6) | NA | NA | |
| Lancellotti et al27 | 163 | Prosp | 70±10 | 57 (35) | Aortic stenosis | 20±19 | Cardiac death, AVR, HF | NA | 81 (50) | NA | 27 (17) | NA | 45 (28) | NA | NA | NA | 65 (52) | NA | NA | |
| Kearney et al4 | 146 | Prosp | 75±11 | 55 (37.6) | Aortic stenosis | 25±6 | All-cause mortality | AMI, cardiac death, HF, AS admission, CVA, arrhythmias | NA | 116 (79) | 49 (34) | 38 (26) | NA | NA | NA | NA | NA | 80 (41) | NA | NA |
| Sarvari et al22 | 167 | Retro | 58±12 | 36 (21.5) | Heart transplant | 12±2 | All-cause mortality | NA | NA | 11 (6.5) | 167 (100) | 20 (12) | NA | NA | NA | NA | NA | NA | NA | NA |
| Dahl et al26 | 125 | Prosp | 75±10 | 46 (36.8) | Aortic stenosis | 60±12 | All-cause mortality | CV mortality, HF hospitalisation | NA | NA | NA | 11 (8.8) | NA | NA | NA | NA | 29 (21) | NA | NA | NA |
| Diller et al20 | 413 | Prosp | 36±13 | 202 (49) | Repair ToF | 34±20 | Sudden cardiac death, malignant arrhythmia | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Buss et al19 | 206 | Prosp | 60±9 | 94 (45) | System amyloidosis | 40±12 | All-cause mortality, heart Tx | NA | NA | NA | NA | NA | NA | NA | NA | NA | 58 (40) | NA | NA | |
| Yingchoncharoen et al23 | 79 | Prosp | 77±12 | 40 (50.6) | Aortic stenosis | 23±20 | Cardiac death | NA | 50 (63) | NA | 19 (24) | NA | NA | NA | NA | NA | NA | NA | NA |
ACEi, ACE inhibitor therapy; AMI, acute myocardial infarction; AS, aortic stenosis; AVR, aortic valve replacement; β-block, β adrenoceptor blocker therapy; CM, cardiomyopathy; CV, cardiovascular; CVA, cardiovascular attack; DM, diabetes mellitus; F/U, follow-up; H chol, hypercholesterolaemia; HF hosp, heart failure hospitalisation; HF, heart failure; HTN, hypertension; IHD, ischaemic heart disease; m, months; MI, myocardial infarction; NA, not available; Prosp, prospective; Retro, retrospective; RVS, revascularisation; STEMI, ST segment elevation myocardial infarction; ToF, tetralogy of Fallot; Tx, transplantation.
This table includes demographics, clinical profile and outcomes.